Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis

被引:1
|
作者
Silverberg, Jonathan I. [1 ]
de Bruin-Weller, Marjolein [2 ]
Calimlim, Brian M. [3 ]
Hu, Xiaofei [3 ]
Ofori, Sarah A. [3 ]
Platt, Andrew M. [3 ]
Teixeira, Henrique D. [3 ]
Eyerich, Kilian [4 ]
Thyssen, Jacob P. [5 ]
机构
[1] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Suite 2B-425,2150 Penn Ave NW, Washington, DC 20037 USA
[2] Dept Dermatol & Allergol, Utrecht, Netherlands
[3] AbbVie Inc, Chicago, IL USA
[4] Univ Freiburg, Med Ctr, Dept Dermatol, Freiburg, Germany
[5] Univ Copenhagen, Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark
关键词
TOPICAL CORTICOSTEROIDS; DOUBLE-BLIND; 3; TRIALS; PLACEBO; AD; ADOLESCENTS; ADULTS;
D O I
10.1089/derm.2023.0153
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: In patients with moderate-to-severe atopic dermatitis (AD), greater skin clearance and itch reduction are associated with more pronounced improvements in quality of life (QoL). Objective: To characterize the aggregate response benefit with upadacitinib versus dupilumab or placebo in patients with moderate-to-severe AD. Methods: Degree of skin clearance and itch response in 3 phase 3 studies (Heads Up [NCT03738397] and Measure Up 1/2 [integrated; NCT03569293/NCT03607422]) were assessed by the Eczema Area and Severity Index (EASI) and Worst Pruritus Numerical Rating Scale (WP-NRS), respectively, using mutually exclusive categories. The aggregate response benefit with upadacitinib over dupilumab or placebo was determined by summing incremental differences for each EASI or WP-NRS category across the full distribution of patient responses. Results: Comparisons across EASI improvement threshold distributions, EASI severity levels, and WP-NRS categories demonstrated an aggregate response benefit favoring upadacitinib over dupilumab as early as week 4 and continuing at weeks 16 and 24. Similar trends were observed for upadacitinib 15 and 30 mg versus placebo. Conclusions: The aggregate response benefit in skin clearance and itch reduction favored upadacitinib 30 mg over dupilumab and upadacitinib 15 or 30 mg over placebo. These benefits may translate to overall greater improvements in patient QoL.
引用
收藏
页码:266 / 274
页数:9
相关论文
共 50 条
  • [1] Dupilumab Treatment Rapidly Improves Itch in Patients With Moderate-to-Severe Atopic Dermatitis
    Silverberg, Jonathan I.
    Chao, Jingdong
    Eckert, Laurent
    Chen, Zhen
    Ardeleanu, Marius
    Shumel, Brad
    Plaum, Stefan
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Gadkari, Abhijit
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 29 - 29
  • [2] DUPILUMAB TREATMENT RAPIDLY IMPROVES ITCH IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Silverberg, J.
    Chao, J.
    Eckert, L.
    Chen, Z.
    Ardeleanu, M.
    Shumel, B.
    Plaum, S.
    Graham, N.
    Pirozzi, G.
    Gadkari, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S95 - S95
  • [3] Efficacy of upadacitinib and dupilumab on achieving stringent and composite skin and itch outcomes: an indirect comparison of adults with moderate-to-severe atopic dermatitis
    Armstrong, April W.
    Hong, H. Chih-Ho
    Calimlim, Brian M.
    Buessing, Marric G.
    Crowell, Marjorie M.
    Silverberg, Jonathan, I
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II26 - II27
  • [4] Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis
    Armstrong, April W.
    Hong, H. Chih-Ho
    Calimlim, Brian M.
    Buessing, Marric G.
    Crowell, Marjorie M.
    Silverberg, Jonathan I.
    DERMATOLOGY AND THERAPY, 2024, 14 (09) : 2457 - 2465
  • [5] Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
    Hamilton, Jennifer D.
    Suarez-Farinas, Mayte
    Dhingra, Nikhil
    Cardinale, Irma
    Li, Xuan
    Kostic, Ana
    Ming, Jeffrey E.
    Radin, Allen R.
    Krueger, James G.
    Graham, Neil
    Yancopoulos, George D.
    Pirozzi, Gianluca
    Guttman-Yassky, Emma
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 134 (06) : 1293 - 1300
  • [6] Dupilumab treatment induces rapid clinical improvement of itch in patients with moderate-to-severe atopic dermatitis
    Silverberg, Jonathan I.
    Eckert, Laurent
    Ardeleanu, Marius
    Chen, Zhen
    Akinlade, Bolanle
    Plaum, Stefan
    Graham, Neil M. H.
    Pirozi, Gianluca
    Gadkari, Abhijit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB113 - AB113
  • [7] Dupilumab in the treatment of moderate-to-severe atopic dermatitis
    Kraft, Magdalena
    Worm, Margitta
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (04) : 301 - 310
  • [8] Efficacy of upadacitinib vs dupilumab for moderate-to-severe atopic dermatitis: analysis of time spent in itch response state from the Heads Up study
    Blauvelt, Andrew
    de Bruin-Weller, Marjolein
    Kwatra, Shawn G.
    Gooderham, Melinda J.
    Kim, Brian
    Liu, Yingyi
    Chu, Alvina D.
    Ofori, Sarah
    Platt, Andrew
    Calimlim, Brian M.
    Silverberg, Jonathan, I
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II28 - II29
  • [9] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    James E. Frampton
    Hannah A. Blair
    American Journal of Clinical Dermatology, 2018, 19 : 617 - 624
  • [10] Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
    Ferrucci, Silvia
    Casazza, Giovanni
    Zussino, Martina
    Tavecchio, Simona
    Marzano, Angelo V.
    Tedeschi, Micol
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (20)